

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 October 2005 (06.10.2005)

PCT

(10) International Publication Number
WO 2005/093085 A1

(51) International Patent Classification⁷: C12Q 1/22, 1/48

(74) Agents: MACLEAN, Martin, Robert et al.; Mathys & Squire, 120 Holborn, London EC1N 2SQ (GB).

(21) International Application Number:

PCT/GB2005/001056

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 22 March 2005 (22.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0406427.5 22 March 2004 (22.03.2004) GB

(71) Applicant (*for all designated States except US*): HEALTH PROTECTION AGENCY [GB/GB]; Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): SUTTON, J., Mark [GB/GB]; Health Protection Agency, Porton Down, Salisbury, Wiltshire SP4 0JG (GB). RAVEN, Neil, David, Hammond [GB/GB]; Health Protection Agency, Porton Down, Salisbury, Wiltshire SP4 0JG (GB).

Published:

— with international search report

[Continued on next page]

(54) Title: BIOLOGICAL INDICATOR



(57) Abstract: A kinase is used in a biological indicator for validation of treatment processes designed to reduce the amount or activity of a biological agent in a sample. The indication can be used for validation of sterilisation treatment. The formation of ATP from a substrate comprising ADP is measured via the luciferin/luciferase system in a luminometer. Thermostable adenylate kinase from *Sulfolobus acidocaldarius* is especially suitable for the validation of procedures to inactivate transmissible spongiform encephalopathy agents.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.